European Cannabis Market Leader Bloomwell Group Secures $10 Million Investment


Ryan Allway

October 18th, 2021

News


Largest Seed Funding Ever Received In European Cannabis Market

– US growth capital provider Measure 8 Venture Partners is lead investor

– Curaleaf executive chairman Boris Jordan joins board

– Investment ushers in new era of “natural based medicine”

– Showcases Germany as the leading European market for medical cannabis

 

FRANKFURT, Germany, Oct. 18, 2021 /CNW/ — The Bloomwell Group has successfully closed a seed funding round of over $10 million dollarsthe highest publicly known seed investment for a European cannabis company to date. The lead investor is US growth capital provider Measure 8 Venture Partners, specialists in cannabis industry investments. Among other investors, business angel Dr. Reinhard Meier is investing again through his Venture Capital Investors fund; and Mr. Weber of FPS acted as legal advisor to Bloomwell.

 

Concurrent with the announcement, the Bloomwell Group, which includes Algea CareEurope’s leading telemedicine company for medical cannabis in terms of patient numbers, is repositioning itself as a holding company, allowing it to build, invest or acquire cannabis companies.

 

“With Bloomwell, we are revolutionizing healthcare through digitalization and the potential of medical cannabis as well as other natural medicines. Our portfolio companies will radically focus on a consumer centric approach along the entire value chain of medical cannabis, with the exception of cultivation. The era of natural based medicine begins now and Bloomwell is taking the lead,” said Niklas Kouparanis, CEO & Co-Founder of Bloomwell Group.

 

Within a year, Bloomwell Group has grown to 160 employees, with projected revenues of five million euros in 2021. In addition to Niklas Kouparanis, CEO, entrepreneur and cannabis pioneer, the board is strengthened by telemedicine veteran Dr. Reinhard Meier, who as founder led Teleclinic to an exit, Co-Founder Samuel Menghistu and Boris Jordan, founding partner of Measure 8 Venture Partners.

 

The accomplished board covers facets in medicine, digitalization, cannabis, investment and brand building across various market sectors.

  • Dr. Reinhard Meier, Director of Radiology at Westpfalz Klinikum, previously founded and invested in several medical companies as well as initiating several VC funds.
  • Boris Jordan, With the $285M acquisition of EMMAC, Curaleaf is the first and only MSO to have a meaningful presence in Europe. Jordan is considered one of the most renowned cannabis experts in North America and has been responsible for the operations of Curaleaf, a global publicly traded cannabis company, as well as venture investments in the cannabis space via Measure 8 Ventures.
  • Niklas Kouparanis, a serial entrepreneur, and a pioneer in the Euopean medical cannabis industry.
  • Samuel Menghistu, spearheading the intersection of banking, investments, M&A Transactions and IPOs for over six years.

 

“Many of the high expectations of both investors and global corporations within the European cannabis industry have not been fulfilled since the enactment of the ‘Cannabis Law’ in March 2017, even though the market has continued to grow steadily. With Bloomwell, we have shown within just one year how much can be achieved through entrepreneurial finesse. The nascent European cannabis industry is full of potential for Bloomwell’s future development. While the market is consolidating elsewhere, all signs point towards growth and expansion through the combination of cannabis, innovation, digitalization and a radical D2C or direct-to-patient approach,” said Anna-Sophia Kouparanis, Co-Founder of the Bloomwell Group.

 

Germany is the leading European market for medical cannabis and the Bloomwell Group has proven within one year that it can identify and scale innovative solutions in this new growth market for the benefit of patients. Cannabis has a bright future in Europe and we look forward to supporting and working with the Bloomwell Group as they continue to scale,” said Boris Jordan, Founding Partner of Measure 8 Venture Partners and Executive Chairman of Curaleaf.   

 

“Digitalization is the key to finally putting patients at the center of an inefficient healthcare system. Algea Care, a portfolio company of Bloomwell, has already proven that it has the expertise and clout to improve the well-being and everyday life of thousands of patients in a highly regulated sector through medical cannabis and digitalization as well as an immensely high service standard,” said Dr. Reinhard Meier.

 

About Bloomwell Group

The Bloomwell Group is a holding company for medical cannabis companies and potentially for companies in a recreational market that may be legal in the future. The mission is to build, acquire and invest in ESG healthcare companies along the entire value chain, with the exception of cultivation. In doing so, Bloomwell Group relies on a patient-centric D2C approach to set up a strong, revolutionising and streamlined Patient Journey to change healthcare for the better. The combination of natural medicines and digitalisation is a journey back to the roots of healthcare with 21st century tools. The green revolution in healthcare starts now and Bloomwell is taking the lead: www.bloomwell.eu.

 

About Measure 8 Venture Partners

Founded in 2018, Measure 8 Venture Partners was created by Boris Jordan to capitalize on the emergence of the U.S. and global cannabis industry and was named by Business Insider as the most active cannabis VC fund during 2020.

 

Press contact:
Lori Rosen
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading